BOSTON ( TheStreet) -- Here's an updated list of biotech and pharmaceutical companies with pending FDA drug approval decisions for the rest of 2012 and into early 2013. The calendar on the following pages captures the most important U.S. regulatory events -- FDA drug approvals and advisory panels -- expected between July and February 2013. As every savvy biotech investor and trader knows, the volatility in biotech and drug stocks ramps significantly as U.S. regulators weigh whether to approve or reject new drugs. Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst. Amarin ( AMRN) Drug/indication: Vascepa for triglyceride reduction Approval decision date: July 26 Horizon Pharmaceuticals ( HZNP) Drug/indication: Lodotra for rheumatoid arthritis pain Approval decision date: July 26 Salix Pharmaceuticals ( SLXP) and Progenics ( PGNX) Drug/indication: Relistor SC for opioid-induced constipation Approval decision date: July 27 This is an additional indication for currently approved Relistor. Regeneron Pharmaceuticals ( REGN) Drug/indication: Arcalyst for prevention of gout flares Approval decision date: July 30 This will be the second approved indication for Arcalyst, which is currently marketed as a treatment for cryopyrin-associated periodic syndromes (CAPS). Regeneron Pharmaceuticals ( REGN) and Sanofi ( SNY) Drug/indication: Zaltrap for colon cancer Approval decision date: Aug. 4 Zaltrap has posted mixed results in phase III clinical trials. Talon Therapeutics ( TLON) Drug/indication: Marqibo for advanced acute lymphoblastic leukemia Approval decision date: Aug. 12 In March, an FDA advisory panel voted to recommend approval of Marqibo. Gilead Sciences ( GILD) Drug/indication: Quad for HIV Approval decision date: Aug. 27 Quad combines four Gilead drugs into a single, once-daily pill for HIV. The new (and still experimental) components in the Quad are the integrase inhibitor elvitegravir and cobicistat, which is used to boost blood levels of elvitegravir. Pfizer ( PFE) Drug/indication: Tofacitinib for rheumatoid arthritis Approval decision date: August (exact date not specified) Tofacitinib would be the first pill approved for the treatment of rheumatoid arthritis, competing with established injectable drugs like Abbbot's Humira. Ironwood Pharmaceuticals ( IRWD) Drug/indication: Linaclotide for chronic idiopathic constipation and irritable bowel syndrome Approval decision date: Sept. 8 Navidea Biopharmaceuticals ( NAVB) Drug/indication: Lymphoseek, a radioactive tracing agent for lymph node mapping Approval decision date: Sept. 10 Regeneron Pharmaceuticals ( REGN) Drug/indication: Eylea for Retinal Vein Occlusion (RVO) Approval decision date: Sept. 21 This is an additional indication for currently approved Eylea. NPS Pharmaceuticals ( NPSP) Drug/indication: Gattex for short bowel syndrome Approval decision date: Sept. 28 Sanofi ( SNY) Drug/indication: Aubagio for multiple sclerosis Approval decision date: Third quarter Celgene Drug/indication: Abraxane for non-small cell lung cancer Approval decision date: Oct. 12 Abraxane is already approved for the treatment of breast cancer.